Perspective Therapeutics, Inc. filed a Form 8-K on November 6, 2026, disclosing that it issued a press release and posted a poster presentation announcing updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for unresectable or metastatic melanoma.

Key Highlights

  • Trial update disclosed: The company released updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01).
  • Target indication: The trial involves patients with unresectable or metastatic melanoma who have demonstrated melanocortin 1 receptor tumor expression, according to the filing.
  • Dual purpose: VMT01 is being studied for both the diagnosis and treatment of the target patient population, the filing states.
  • Conference venue: Results are being presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, held November 4-8, 2026, in Phoenix, Arizona.
  • Exchange listing: Common stock is listed on NYSE American under the symbol CATX.
  • Signed by: The filing was signed by Johan (Thijs) Spoor, Chief Executive Officer, on November 6, 2026.

Perspective Therapeutics Discloses VMT01 Phase 1/2a Interim Results at SITC Annual Meeting

According to the Form 8-K filed with the U.S. Securities and Exchange Commission, Perspective Therapeutics, Inc. (NYSE American:CATX) reported on November 6, 2026, that it issued a press release and posted a poster presentation containing updated interim results from its ongoing Phase 1/2a clinical trial. The trial evaluates [212Pb]lapemelanotide zapixetar, referred to in the filing as VMT01, in patients with unresectable or metastatic melanoma who have demonstrated melanocortin 1 receptor tumor expression.

The filing states that the presentation covers the compound's use for both diagnosis and treatment of the identified patient population. The poster was presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, taking place November 4-8, 2026, in Phoenix, Arizona. The company disclosed that a copy of the press release was filed as Exhibit 99.1 and the poster presentation as Exhibit 99.2, each incorporated by reference into the filing.

The 8-K was filed under Item 8.01 (Other Events) and was signed by Chief Executive Officer Johan (Thijs) Spoor. No financial statements were included. The filing does not provide specific clinical outcome data within the body of the form itself; the detailed interim results are contained in the attached exhibits.

What Was Disclosed

Perspective Therapeutics filed an 8-K on November 6, 2026, to report updated interim Phase 1/2a clinical trial results for VMT01 in melanoma patients, shared via press release and a poster at the SITC 2026 annual meeting in Phoenix, Arizona.